Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, Kitazono T, Ueno S, Taguchi R, Yoshihiro T, Doi Y, Arimizu K, Ohmura H, Kajitani T, Nio K, Nakano M, Oshima K, Tamura S, Shirakawa T, Shimokawa H, Uchino K, Hanamura F, Okumura Y, Komoda M, Isobe T, Ariyama H, Esaki T, Hashimoto K, Komune N, Matsuo M, Matsumoto K, Asai K, Yoshitake T, Yamamoto H, Oda Y, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: ariyama h. BMC Cancer. 2023 Oct 31;23(1):1046. doi: 10.1186/s12885-023-11528-4. BMC Cancer. 2023. PMID: 37904096 Free PMC article.
Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.
Nio K, Higashi D, Kumagai H, Arita S, Shirakawa T, Nakashima K, Shibata Y, Esaki M, Manabe T, Nagai S, Ueki T, Nakano M, Ariyama H, Kusaba H, Hirahashi M, Oda Y, Esaki T, Mitsugi K, Futami K, Akashi K, Baba E. Nio K, et al. Among authors: ariyama h. Anticancer Drugs. 2016 Jun;27(5):457-63. doi: 10.1097/CAD.0000000000000338. Anticancer Drugs. 2016. PMID: 26771865
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E. Takayoshi K, et al. Among authors: ariyama h. Cancer Chemother Pharmacol. 2017 Aug;80(2):333-342. doi: 10.1007/s00280-017-3371-0. Epub 2017 Jun 26. Cancer Chemother Pharmacol. 2017. PMID: 28653251 Free article.
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E. Makiyama A, et al. Among authors: ariyama h. Gastric Cancer. 2018 May;21(3):464-472. doi: 10.1007/s10120-017-0759-9. Epub 2017 Aug 10. Gastric Cancer. 2018. PMID: 28799048
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer.
Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E. Yamaguchi K, et al. Among authors: ariyama h. Cancer Chemother Pharmacol. 2018 Oct;82(4):625-633. doi: 10.1007/s00280-018-3652-2. Epub 2018 Jul 24. Cancer Chemother Pharmacol. 2018. PMID: 30043209
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T, Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K, Baba E. Tanoue K, et al. Among authors: ariyama h. Sci Rep. 2021 Feb 2;11(1):2741. doi: 10.1038/s41598-021-82448-1. Sci Rep. 2021. PMID: 33531609 Free PMC article.
116 results